Key Takeaways
- Record FY25, but FY26 guided down sharply: FY25 delivered highest-ever revenue (INR4,784 crores, +16%) and profit (INR1,883 crores, +36%), yet management guided for a possible 20% revenue dip and 30% profit dip in FY26, citing geopolitical uncertainties.
- Q4 profit hit by one-off charges: Q4 profit of INR406 crores absorbed an INR50 crore Crop Health impairment, a ~INR25 crore U.S. chargeback adjustment, and higher R&D spend, masking underlying operational performance.
- Revlimid erosion is tracking to plan: Management has always been conservative on Revlimid, and the pace of erosion is fitting expectations; profit share from the new quota shipped to Teva will continue to flow in coming quarters.
- The pipeline is binary and back-end loaded: Two major India launches (Risdiplam, Semaglutide) and an NCE trial readout all sit 12-18 months out, making FY26 a year where execution must carry the story while catalysts mature.
- What to watch next quarter: The Risdiplam court order (expected June 2025), any inorganic deal closure, and whether the Crop Health business shows progress toward its breakeven target of INR160-170 crores revenue.
FY26 Guidance: The Downward Reset
- Topline and bottomline contraction: Management estimates a possible dip in revenue by 20% and profits by 30% for FY26, driven by geopolitical uncertainties that have been factored into the outlook.
- First-half strong, second-half weaker: The guidance shape is explicitly front-loaded: the June and September quarters should do well, after which performance becomes difficult to judge and will not be as strong as H1.
- Too many moving parts to pin down: Management has assumed certain things on political risk, portfolio changes, and R&D expenditure, but declined to attribute specific outcomes to specific events, calling the environment unpredictable.
- R&D spend rises with the ambition: FY26 R&D expenditure is targeted at up to INR400 crores, and the linkage to EBITDA means future spend will be calibrated to the surplus generated that year.
Rajeev Nannapaneni: "I think people are harsh when you say something higher and then we deliver, then market is harsh. So, it's better to say something less then deliver more. So, I think that's what I've learned."
Pipeline Catalysts: Binary Outcomes, Distant Timelines
- Risdiplam litigation nears resolution: One last hearing remains, expected to be reserved for order by end of May 2025, with an order from the Delhi High Court post-holidays in June; if favorable, the company can launch immediately and will have first-mover advantage.
- Semaglutide filed as sole FTF: Filed in April 2024 as the sole first-to-file; a clinical trial has already started in India, and launch is expected maybe by the end of the financial year, with market formation anticipated early next year.
- NRC-2694 trial is a slow burn: The Phase II trial for late-stage head and neck cancer has recruited 10-20 patients so far against a target of 60-70; management hopes to reach that enrollment in the next 1-1.5 years and expects clarity on the NCE molecule in 12-18 months.
- Recruitment challenges are real: The trial targets patients who have failed KEYTRUDA, and recruitment has been difficult; protocol amendments have been made, but the outcome hinges on patient enrollment velocity.
- Other U.S. filings stack up: Seven to eight filings are targeted, including Olaparib (subject to legal clarity), Erdafitinib, Capmatinib, and shared FTFs on Yondelis, Carfilzomib, and Ibrutinib (subject to legal outcomes).
Rajeev Nannapaneni: "Moonshots make money, don't discount moonshots. A lot of our moonshots have been successful."
Revlimid: The Managed Decline
- Erosion is tracking conservatively: Management has always been conservative on Revlimid assumptions, and the actual erosion is fitting in pretty much with expectations, providing a predictable, if declining, profit stream.
- Profit share mechanics: For the new quota, some amount was booked in the March quarter; the company has already shipped the quantity to Teva and is now booking only the profit share, which will continue in coming quarters.
- No explicit lag confirmation: When asked about the lag between Teva's sales and profit recognition, management addressed the current quarter booking but did not directly confirm or deny the lag structure described by the analyst.
India Business: Base Growth Plus Launch Optionality
- Base business growing steadily: The underlying India business should grow around 7% to 10%, providing a stable foundation before any launch contributions.
- Two big ideas can transform the trajectory: Risdiplam (subject to court decision) and Semaglutide (expected maybe end of the financial year) are the swing factors; if both come through, India growth will be much more than 8-10%, pointing to substantial improvement in sales next year.
- Semaglutide supply chain set up: The company is using a CMO (One Source) for the cartridge, and in Canada is tied up with Mylan (Viatris) rather than going direct.
Crop Health & Other Segments: The Turnaround Bet
- A business that has not made money: The Crop Health Science business has underperformed for 2-3 years, prompting an INR50 crore non-cash impairment on property, plant and machinery that can be reversed if profitability returns.
- Breakeven is the first milestone: Management expects to hit critical mass this year to start breaking even, needing about INR160-170 crores revenue to be EBITDA positive, and believes they are at the end of the tunnel.
- Cash flow tells a better story: Despite INR60 crores in sales, cash flow was INR85-90 crores, which management points to as the true indicator of product sell-through; the sales reduction partly reflects returns from a product stopped two years ago.
- Non-U.S. markets performing well: The company is doing very well in MENA, Canada, and Brazil with very good launches, driven by a basket of cancer products; growth should be healthy.
- Land monetization is a slow-burn asset: Land sold to Microsoft for a data centre at a good rate; remaining property one hour from Hyderabad can be monetized over a 4- to 5-year view.
Strategic Bets: NCEs, Cell & Gene Therapy, and Inorganic Moves
- Building a pipeline of 15 ideas: The NCE and cell/gene therapy strategy aims to build a portfolio of about 15 candidates; even if 6 or 7 work, that is the goal, with a mix of smaller and larger investments including the $8 million stake in eGenesis.
- Inorganic deals are in the works: The company is pursuing a couple of acquisitions and hopes to close something this financial year; one target being considered is a manufacturing or distribution base in the U.S.
- Kothur plant still in remediation: Remedial action is ongoing and the company has not yet informed the USFDA for reinspection; supply continues from the site but no new approvals are being granted.
Rajeev Nannapaneni: "I think you have to reimagine your business every few years, right? So, I mean, a pure generics play is going to be very competitive and your moonshot ideas cannot stick only to generics, right? You need to also look at NCE."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY26 revenue and profit | Possible dip in revenue by 20% and profits by 30% | FY26 full year |
| FY26 R&D spend | Targeting up to INR400 crores | FY26 |
| India base business growth | 7% to 10% growth | FY26 |
| Risdiplam launch | Launch immediately if court order is favorable | Order expected June 2025 |
| Semaglutide launch | Expected maybe end of the financial year | FY26 |
| Crop Health breakeven | Hit INR160-170 crores revenue to be EBITDA positive | This year (FY26) |
| NRC-2694 trial enrollment | Recruit 60-70 patients | Next 1-1.5 years |
| NCE molecule clarity | Clarity on where the trial is going | Next 12-18 months |
| Inorganic deal closure | Close a deal, possibly a U.S. manufacturing or distribution base | This financial year (FY26) |
| U.S. filings | 7 to 8 filings targeted | FY26 |
Key Metrics
| Metric | Q4 FY25 |
|---|---|
| Consolidated revenue | ₹1,287.3 cr, vs ₹1,110.3 cr in Q4 FY24 |
| Consolidated net profit | ₹406 cr, vs ₹386.3 cr in Q4 FY24 |
| Full-year FY25 consolidated revenue | ₹4,784 cr, +16% YoY |
| Full-year FY25 consolidated net profit | ₹1,883.4 cr, +36% YoY |
| FY26 revenue guidance | ~20% dip expected, due to geopolitical uncertainties |
| FY26 PAT guidance | ~30% dip expected |
| R&D spend (FY25) | ₹373 cr, 8.5% of stand-alone revenue |
| R&D spend (FY26 target) | Up to ₹400 cr |
| Cash position | Over ₹3,500 cr |
| Impairment charge (Crop Health Science) | ₹50 cr, related to property, plant and machinery |
| Chargeback adjustment (U.S. subsidiary) | ~₹25 cr |
| India base business growth expectation (FY26) | 7% to 10% |
| Crop Health Science net revenue (FY25) | ~₹60 cr |
| Crop Health Science segment loss (FY25) | ~₹150 cr, including impairment |
| Non-U.S. formulation exports (FY25, estimate) | ~₹800 cr to ₹900 cr |
| Annual capex run-rate | ~₹300 cr to ₹350 cr |